Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | SI | P14410 | 2/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11687845 | 0.81 | HSD17B10 (0.52) | HSD17B10CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL26754370 | 0.78 | HSD17B10 (0.46) | HSD17B10CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL9260657 | 0.77 | — | — | |
| SCHEMBL1376392 | 0.75 | HSD17B10 (0.47) | HSD17B10CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL19929592 | 0.74 | HSD17B10 (0.44) | HSD17B10CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL10285411 | 0.71 | HSD17B10 (0.44) | HSD17B10CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL5576562 | 0.70 | GAA (0.36) | GAA | |
| SCHEMBL5576969 | 0.70 | GAA (0.36) | GAA | |
| SCHEMBL5576929 | 0.70 | GAA (0.36) | GAA | |
| SCHEMBL193551 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271274-B2 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | AHTEROGENICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | CRABTREE ACQUISITION CO, LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2005112914-A2 | PHENOLIC ANTIOXIDANTS FOR THE TREATMENT OF DISORDERS INCLUDING ARTHRITIS, ASTHMA AND CORONARY ARTERY DISEASE | ATHEROGENICS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | MPO, ALOX15B, ALOX12 | HSD17B10 173/4885CYP3A4 352/4885MAPT 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.